866-997-4948(US-Canada Toll Free)

Prostate Cancer - Pipeline Assessment and Market Forecasts to 2020

Published By :

GlobalData

Published Date : Dec 2010

Category :

Cancer

No. of Pages : 203 Pages


GlobalData, the industry analysis specialist, has released its new report, “Prostate Cancer - Pipeline Assessment and Market Forecasts to 2020”. The report is an essential source of information and analysis on the global prostate cancer therapeutics market. The report provides detailed overview on various treatment options that are currently used in the treatment of prostate cancer. The report identifies the key trends shaping and driving the global prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global prostate cancer sector. 

Scope 

The scope of the report includes:

  • Detailed overview on the symptoms, diagnosis and treatment of prostate cancer.
  • Annualized global prostate cancer therapeutics market revenue data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. Global drug sales forecasts (2001 to 2020) including the sales forecasts of the most promising pipeline therapies.
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China.
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • Analysis of the current and future market competition in the global Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the prostate cancer market.
Reasons to buy 

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global prostate cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
Table of Content

1 Table of contents

1.1 List of Tables
1.2 List of Figures

2 Disease Overview

2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Prostate Specific Antigen Test
2.5.3 Transrectal Ultrasound
2.5.4 Prostate Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.8 Treatment Guidelines

3 Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers & Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 Key Takeaway

4 Competitor Assessment

4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Product Profiles
4.2.1 Taxotere (docetaxel)
4.2.2 Casodex (Bicalutamide)
4.2.3 Zoladex (Goserelin)
4.2.4 Provenge (sipuleucel-T)
4.2.5 Jevtana (cabazitaxel)
4.2.6 Eligard (leuprolide acetate)
4.2.7 Lupron (Leuprolide acetate)
4.2.8 Prostap (leuprolide acetate)
4.2.9 Firmagon (degarelix)
4.2.10 Vantas (Histrelin)
4.2.11 Novantrone (Mitoxantrone hydrochloride)
4.2.12 Emcyt (estramustine)
4.2.13 Trelstar (triptorelin)
4.2.14 Eulexin
4.2.15 Delestrogen
4.2.16 Gynodiol
4.2.17 Estrace tablet
4.2.18 Tace
4.2.19 Nilandrone
4.2.20 Premarin

5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development
5.6 Partners in Research and Development
5.6.1 Licensing Agreements by Phase of Development
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
5.7 Most Promising Drugs’ Profiles
5.7.1 Aflibercept (VEGF Trap)
5.7.2 Ipilimumab
5.7.3 Abiraterone Acetate (CB7630)
5.7.4 MDV3100
5.8 Prostate Cancer Pipeline - Pre-clinical Phase
5.9 Prostate Cancer Pipeline - Phase I
5.10 Prostate Cancer Pipeline - Phase II
5.11 Prostate Cancer Pipeline - Phase III
5.12 Prostate Cancer Pipeline - Phase III (Recent Updates)
5.13 Key Takeaway

6 Unmet Need and Target Product Profile
6.1 Unmet Need
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy
6.2 Opportunity for Target Product
6.3 Target Product Profile
6.3.1 Ideal Characteristics
6.3.2 Target Product Description
6.4 Key Takeaway

7 Strategic Assessment

7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway

8 Company Profiles

8.1 Sanofi-aventis
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.4 Oncology Focus
8.2 Pfizer Inc.
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.4 Oncology Focus
8.3 AstraZeneca
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.4 Oncology Focus
8.4 Bristol-Myers Squibb
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 SWOT Analysis
8.4.4 Oncology Focus
8.5 Medivation
8.5.1 Business Description
8.5.2 SWOT Analysis
8.5.3 Oncology Focus
8.6 Takeda Pharmaceuticals
8.6.1 Business Description
8.6.2 SWOT Analysis
8.7 Dendreon Corporation
8.7.1 Business Description
8.7.2 SWOT Analysis
8.8 Johnson and Johnson
8.8.1 Business Description
8.8.2 SWOT Analysis
8.8.3 Oncology Focus
8.9 Auron Healthcare GmbH
8.9.1 Business Description
8.10 Oncogenex Pharmaceuticals, Inc.
8.10.1 Business Description
8.11 Agennix AG
8.11.1 Business Description
8.12 GTx, Inc.
8.12.1 Business Description
8.13 GlaxoSmithKline plc.
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.4 Oncology Focus

9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel validation
9.3.6 Contact Us
9.3.7 Disclaimer
9.3.8 Sources

List of Table


Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 10
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 13
Table 3: Prostate Cancer, Global, Sales Value ($m), 2001-2009 20
Table 4: Prostate Cancer, Top Seven Countries, Sales Value ($m), 2001-2009 21
Table 5: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 22
Table 6: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2001-2009 23
Table 7: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2001-2009 24
Table 8: Prostate Cancer, Top Seven Countries, Patient Volume, 2001-2009 25
Table 9: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2001-2009 26
Table 10: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2001-2009 27
Table 11: Prostate Cancer Therapeutics Market, Global, Sales Value ($m), 2009-2020 31
Table 12: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m), 2009-2020 32
Table 13: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2020 33
Table 14: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2009-2020 34
Table 15: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2009-2020 35
Table 16: Prostate Cancer Therapeutics Market, Top Seven Countries, Patient Volume (000s), 2009-2020 36
Table 17: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2009-2020 37
Table 18: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2009-2020 38
Table 19: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 42
Table 20: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 42
Table 21: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 44
Table 22: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 44
Table 23: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 47
Table 24: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 48
Table 25: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 49
Table 26: Prostate Cancer, Global, Benchmarking Major Marketed Products, 2010 52
Table 27: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 57
Table 28: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 64
Table 29: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 65
Table 30: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 66
Table 31: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 68
Table 32: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 69
Table 33: Prostate Cancer, Global, Licensing Agreements, 2009-2010 95
Table 34: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 97
Table 35: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 98
Table 36: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 106
Table 37: Prostate Cancer, Global, Phase I Pipeline, August 2010 108
Table 38: Prostate Cancer, Global, Phase II Pipeline, August 2010 110
Table 39: Prostate Cancer, Global, Phase III Pipeline, August 2010 117
Table 40: Prostate Cancer, Global, Phase III Pipeline (Recent Updates), November 2010 118
Table 41: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 125
Table 42: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 126
Table 43: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 183
Table 44: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 184

List of Chart


Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19
Figure 2: Prostate Cancer, Global, Sales Value ($m), 2001-2009 20
Figure 3: Prostate Cancer, Top Seven Countries, Sales Value ($m), 2001-2009 21
Figure 4: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 22
Figure 5: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2001-2009 23
Figure 6: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2001-2009 24
Figure 7: Prostate Cancer Therapeutics Market, Top Seven Countries , Patient Volume (000s), 2001-2009 25
Figure 8: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2001-2009 26
Figure 9: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2001-2009 27
Figure 10: Prostate Cancer, Global, Market Drivers and Restraints, 2009 29
Figure 11: Prostate Cancer Therapeutics Market, Global, Historical Events Impact on the Market, 2010 30
Figure 12: Prostate Cancer Therapeutics Market, Global, Sales Value ($m), 2009-2020 31
Figure 13: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m), 2009-2020 32
Figure 14: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2020 33
Figure 15: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2009-2020 34
Figure 16: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2009-2020 35
Figure 17: Prostate Cancer Therapeutics Market, Top Seven Countries, Patient Volume (000s), 2009-2020 36
Figure 18: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2009-2020 37
Figure 19: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2009-2020 38
Figure 20: Prostate Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2009-2020 40
Figure 21: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 41
Figure 22: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 43
Figure 23: Prostate Cancer Therapeutics Market, Global, Breakdown of Drug Sales (%), 2009 45
Figure 24: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 50
Figure 25: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 51
Figure 26: Prostate Cancer, Global, Taxotere, Chemical Structure 53
Figure 27: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 55
Figure 28: Prostate Cancer, Global, Casodex, Chemical Structure 56
Figure 29: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010 59
Figure 30: Prostate Cancer, Global, Zoladex, Chemical Structure 60
Figure 31: Prostate Cancer, Global, Eligard , Chemical Structure 64
Figure 32: Prostate Cancer, Global, Lupron, Chemical Structure 67
Figure 33: Prostate Cancer, Global, Firmagon, Chemical Structure 72
Figure 34: Prostate Cancer, Global, Vantas, Chemical Structure 73
Figure 35: Prostate Cancer, Global, Novatrone, Chemical Structure 75
Figure 36: Prostate Cancer, Global, Emcyt, Chemical Structure 77
Figure 37: Prostate Cancer, Global, Trelstar, Chemical Structure 78
Figure 38: Prostate Cancer, Global, Eulexin, Chemical Structure 80
Figure 39: Prostate Cancer, Global, Delestrogen, Chemical Structure 82
Figure 40: Prostate Cancer, Global, Gynodiol, Chemical Structure 83
Figure 41: Prostate Cancer, Global, Estrace, Chemical Structure 84
Figure 42: Prostate Cancer, Global, Tace, Chemical Structure 85
Figure 43: Prostate Cancer, Global, Nilandrone, Chemical Structure 86
Figure 44: Prostate Cancer, Global, Premarin, Chemical Structure 87
Figure 45: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 88
Figure 46: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 89
Figure 47: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 90
Figure 48: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 91
Figure 49: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 92
Figure 50: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 93
Figure 51: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 96
Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 99
Figure 53: Prostate Cancer, Global, Abiraterone, Chemical Structure 102
Figure 54: Prostate Cancer, Global, MDV3100, Chemical Structure 104
Figure 55: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 119
Figure 56: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 120
Figure 57: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 120
Figure 58: Prostate Cancer, Global, Prostate Cancer, Opportunity and Unmet Need, 2010 121
Figure 59: Prostate Cancer, Global, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 124
Figure 60: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 124
Figure 61: Prostate Cancer, Global, Key Events Impacting the Future Market 127
Figure 62: Prostate Cancer, Global, Implications for Future Market Competition, 2010 128
Figure 63: Prostate Cancer, Global, Future Players in the Market, 2010 130
Figure 64: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 132
Figure 65: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 133
Figure 66: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 134
Figure 67: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 139
Figure 68: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 141
Figure 69: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 147
Figure 70: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 148
Figure 71: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 150
Figure 72: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 151
Figure 73: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 155
Figure 74: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 155
Figure 75: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 156
Figure 76: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 157
Figure 77: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 158
Figure 78: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 164
Figure 79: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 165
Figure 80: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 166
Figure 81: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 170
Figure 82: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 172
Figure 83: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 177
Figure 84: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 184
Figure 85: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 187
Figure 86: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 193
Figure 87: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 194
Figure 88: GlobalData Market Forecasting Model 200

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *